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Background: Excessive bleeding after cardiopulmonary bypass (CPB) is risk factor for adverse outcomes after
elective cardiac surgery (ECS). Although many different point-of-care devices to diagnose hemostatic disturbances
after CPB are available, the best test is still unclear. The study aim was to compare the accuracy of hemostatic
disorder detection between two point-of-care devices.
Methods: We enrolled 148 patients (105 male and 43 female) undergoing ECS in a prospective observational study.
Rotational thromboelastometry (TEM, with InTEM test), and Activated coagulation time (ACT) measurement were
performed 15 min after protamine administration. The cohort group was divided into two subgroups according to
occurrence of excessive postoperative bleeding. Endpoints were defined in two ways: as total amount of chest tube
output (CTO) and blood product transfusion requirements.
Results: Total amount of CTO value of 1507,50 mL presented 75th percentile of distribution, thus cut-off value for
bleeder category. InTEM parameters, but not ACT, correlated significantly with CTO. InTEM parameters with the
strongest correlation to CTO were tested for accuracy in predicting excessive postoperative bleeding using ROC
analysis. InTEM A 10 value of 38 mm, InTEM A 20 value of 49 mm and InTEM A 30 value of 51 mm delineated
bleeding tendency. Patients with total amount of CTO exceeding 75th percentile were more frequently transfused
with fresh frozen plasma (51.4% vs. 9.9%, p < 0.001), fibrinogen concentrate (21.6% vs. 2.7%, p = 0.001) and platelet
concentrate (13.5% vs. 0.9%, p = 0.004).
Conclusion: Our study showed that InTEM test, but not ACT is useful in prediction of bleeding tendency after
protamine administration following weaning from CPB. InTEM test could be used as a first line test in screening of
possible hemostatic disorder following protamine administration.
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Excessive bleeding after CPB continues to be an import-
ant cause of morbidity and mortality [1]. Dixon B et al.
reported chest tube output (CTO) as the strongest inde-
pendent predictor of mortality [2]. However, the question
how to predict and prevent excessive bleeding due to
hemostatic disturbances remains challenging. Therapeutic
approach to surgically or coagulopathically-induced bleed-
ing is quite different. In addition to, conventional coagula-
tion tests are not able to predict postoperative bleeding
[3,4]. Thus, bedside suitable devices capable to identify
hemostatic disturbances after weaning from cardiopulmo-
nary bypass (CPB) are desirable. Identifying hemostatic
disorder after CPB may make the important differentiation
between coagulopathic (nonsurgical) bleeding requiring
procoagulant blood components transfusion and surgical
bleeding requiring surgical intervention.
The Activated Coagulation Time (ACT) was first de-
scribed by Hattersley in 1966 and is essentially a point-
of-care test of coagulation that is used to monitor the
anticoagulant effect of unfractionated heparin (UFH) in
patients on bypass surgery [5]. The ACT first came into
clinical use in the mid-1970s to guide the administration
and reversal of heparin during CPB procedures. Although
originally proposed as a routine pre-operative screening
test - it is now used almost exclusively for monitoring pa-
tients on CPB. The test is now more commonly performed
using a fully automated technique with several devices
available in which the end point i.e. clot formation is re-
corded electronically – the principle, however, remains the
same as described by Hattersley many years ago [5]. ACT is
the most common intraoperative point-of-care hemostatic
test to confirm profound anticoagulation during CPB and
adequacy of heparin-protamine neutralization after wean-
ing from CPB [6]. Although the most commonly used
hemostatic point-of-care device in cardiosurgical proce-
dures, the ACT is the least sensitive hemostatic test to de-
tect residual heparin anticoagulation [6], as well as other
hemostatic disorders which may lead to excessive bleeding
after CPB. Although ACT is regularly used for assessment
of heparine-protamine neutralization management ad-
equacy and assesses intrinsic pathway of coagulation, its
reliability in predicting hemostatic disorder resulting in
excessive bleeding remains elusive. The best point-of-care
test to diagnose hemostatic disorder immediately after
CPB, is still unclear. Rotation thromboelastometry (TEM)
performed on whole blood samples provides information
on the contribution of fibrinogen and platelets to clot for-
mation, however, the precise relationship between TEM
values and postoperative bleeding still remains unclear.
This study sought to compare and determine the accur-
acy of intrinsically activated rotational TEM test (InTEM
test) variables and ACT in detection of excessive bleeding
and blood products transfusion requirements after CPB.This study has been presented during 23rd World Con-
gress of the World Society of Cardio-Thoracic Surgeons
and published in supplement issue of the Journal of Car-
diothoracic Surgery [7].
Methods
This study presents retrospective exploratory analysis of
prospectively collected data within research project ap-
proved by the Ethics Committee of the University Hospital
Center Zagreb and registered at the Clinical-trials.gov web-
site (Identifier NCT01281397). The purpose of this study
was prospectively defined. Clinical trial NCT01281397
was designed in prospective observational fashion. The
aim of trial was to assess possibility of point-of-care
hemostatic devices (rotational thromboelastometry and
multiple electrode aggregometry) to predict excessive
bleeding in elective cardiac surgery. Parameters of rota-
tional thromboelastometry and multiple electrode aggrego-
metry were obtained perioperatively at three time points
and respective values were correlated with observed key
endpoints such as CTO and transfusion requirements.
Initially, a trial was supposed to recruit 400 patients. Dur-
ing study period, interim statistical analysis was performed
after approximately every 50 patients. After 148 patients
enrolled, interim analysis revealed positive results in regard
to primary hypothesis that point-of-care tests for assess-
ment of platelet function and viscoelastic blood properties
predict bleeding in cardiac surgery patients. Thus, due to
fact that positive results confirmed primary hypothesis
after 148 patients were recruited, we decided to terminate
study earlier.
Patient selection
After approval by the local School of Medicine and
University Hospital Center Ethics Committee and written
informed consent, 148 consecutive patients (male, n = 105
(70.9%); female, n = 43 (21.9%)), scheduled for elective car-
diac surgery (ECS) procedures requiring CPB between July
2010 and January 2011 were recruited. Excluding criteria
were: age younger than 18 years, urgent procedure, ad-
ministration of antiplatelet agents other than aspirin and
clopidogrel, patients with inaccurate antiplatelet therapy
administration documentation, patients with off-pump
cardiac surgical procedure, and patients requiring surgical
exploration for excessive bleeding due to obvious surgical
bleeding with a bleeding vessel identified.
Perioperative management
All patients had the same anesthetic and perfusion teams,
and were admitted at least 1 day before surgery. Surgery
was performed by using a standard technique. All mea-
surements were performed by research fellow, not directly
included in treating patients. The nurses, anesthesiolo-
gists, and surgeons managing the patient's care were
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single unit with standard surgical techniques. Surgical
bleeding was controlled with diathermy and bone wax.
The patients received diazepam and morphine 30 min
prior to the induction of anesthesia. Endotracheal tube,
urinary catheter, as well as radial artery and pulmonary
artery catheters were inserted. The anesthetic regime
included induction and maintenance of anesthesia with
midazolam, fentanyl and pancuronium bromide. This
was coupled with sevoflurane inhalation. The initial ven-
tilator settings included a tidal volume of 8 ml kg_1, and
a respiratory rate of 12 breaths per minute. Typically,
the FiO2 was set at 50%. Cardiopulmonary circuit con-
sisted of the Medtronic Affinity Trillium membrane oxy-
genator, venous reservoir and PVC tubing (Medtronic,
Minneapolis, MN, USA) and a Stoeckert III roller pump
(Stoeckert, Munich, Germany). Flow at 2.2 l min-1 m-2
and mean blood pressure of 60 mmHg were targeted.
Heart was arrested with cold blood cardioplegia. Before
CPB, 300 U/kg of heparin were administered. An add-
itional 10000 units of heparin were included in the by-
pass circuit. Heparin dosing during CPB was based on
ACT results repeated every 30 minutes. Systemic hepar-
inisation aiming at an activated clotting time >480 s was
used, followed by full reversal with protamine after
decannulation. An additional heparin bolus dose (50 to
70 U/kg) was administered if an ACT value was less than
480 seconds. At the conclusion of CPB, the total heparin
dose was antagonized using 1.0 mg of protamine for
each 100 U of heparin. If the ACT exceeded value of
150 sec after protamine administration, additional dose
of 50 mg of protamine was administered. 15 minutes
after protamine administration, a blood sample was ob-
tained to determine both the ACT and InTEM tests. A
dose of 1 g tranexamic acid was given at the induction
of anesthesia and after protamine administration. Ino-
tropic support was initiated in order to maintain a cardiac
index greater than 2.2 l min-1 m-2. Weaning from CPB
was initiated once the patient’s rhythm had stabilized and
normothermia had been achieved. Cardiotomy suction
returned blood to the CPB circuit. Packed red blood cells
(PRBC) were transfused if hematocrit was <20% during
CPB and < 25% after terminating CPB, or when significant
bleeding was obvious. Volume replacement in the inten-
sive care unit was administered as deemed necessary by
the attending physician using hydroxyethyl starch 6% 130/
0.4 and lactated Ringer's solution, PRBC's were transfused
if deemed necessary by the consultant anesthesiologist.
Fresh frozen plasma (FFP) was given in cases showing
prolonged prothrombin time (less than 45%), or according
to clinical decision by the consultant anesthesiologist.
Fibrinogen concentrate and platelet transfusion were ad-
ministered in cases of excessive bleeding at discretion of
consultant anesthesiologist. We do not have specific cut-of values for transfusion of fibrinogen concentrate as well
as platelet concentrate. If patient was exposed to antiplate-
let drugs in close proximity to surgery, transfusion of
platelet concentrate was considered. However, in cases
where coronary revascularization has been performed, ad-
ministration of platelet concentrate was avoided whenever
possible and fibrinogen concentrate was used as a first line
therapy instead.
Blood sampling
Blood samples for InTEM and ACT measurements were
obtained 15 minutes after protamine administration via
central venous port. For InTEM test blood was collected
in 1.8 mL sodium citrate (0.109Molar/3.2% citrate con-
centration) Vacutainer® plastic tubes. InTEM tests were
performed in up to 20 minutes after blood withdrawal.
We used two point of care (POC) devices for hemostatic
properties assessment.
Modified rotational thromboelastometry (TEM)
TEM was performed according to the manufacturer'
instruction using equipment and kits provided by TEM
International GmbH, Munich, Germany. TEM provides
a continuous measure of the clot firmness, whose ampli-
tude is given in milimeters. Technical details of the TEM
analyzer have already been described elsewhere [8]. Put
briefly, by digital data processing, the following typical var-
iables are obtained: clotting time (CT), the time from the
start of measurement until the onset of clotting; Clot for-
mation time (CFT), the time between the onset of clotting
and the moment when the clot firmness reaches an ampli-
tude of 20 mm; A 10, A 20, A 30 corresponds to the max-
imum amplitude of the curve after 10, 20 and 30 minutes,
respectively. INTEM is a baseline test that uses an ellagic
contact activator for analyzing the general cagulatory sta-
tus of the patient.
Activated coagulation time (ACT)
ACT measurements were performed 15 minutes after
protamine administration, with the technique of Kurec
et al. [9]. ACT was first described by Hattersley in 1966
[5] and is a point-of-care test that is used to monitor the
anticoagulant effect of unfractionated heparin. We used
Medtronic ACT Plus™ (Medtronic Perfusion Systems,
Minneapolis, MN) a microprocessor-controlled coagula-
tion instrument used for in vitro real-time clot detection
during CPB. Medtronic ACT Plus has multiple testing
applications. The High Range ACT (HR-ACT) is a func-
tional evaluation of the intrinsic coagulation system. The
endpoint of the test is clot formation. This is detected by
the change in fall rate of which is detected by a photo-
optical system. Clotting is initiated through surface con-
tact with a kaolin activator. The test is performed on
0,4 mL of fresh whole blood per cartridge channel
Table 1 Basic demographic, laboratory and operative
data statistics of study cohort for continuous variables
Number of
patients
Median Interquartile
range
Age (years) 148 66,00 56,50-73,00
Body mass index (kg/m2) 148 28,22 25,72-31,35
Body surface area (m2) 148 1,97 1,82-2,13
EURO score (%) 148 3,15 1,83-5,57
Ejection fraction (%) 148 58,50 49,00-65,00
Platelet count (x109/L) 148 205,50 172,00-250,00
Fibrinogen (g/L) 148 3,85 3,30-4,55
Hemoglobine (g/L) 148 135,00 123,00-145,00
Hematocrit 148 0,41 0,37-0,43
International normalized
ratio
148 0,98 0,94-1,05
Cross-clamp time (min) 148 67,50 50,00-94,00
Cardiopulmonary bypass
time (min)
148 98,00 75,50-127,00
InTEM CT 148 194,00 173,50-215,00
InTEM CFT 148 126,00 100,50-176,50
InTEM alfa 148 68,00 62,00-74,00
InTEM A10 148 45,00 39,00-49,00
InTEM A20 148 53,00 47,00-57,00
InTEM A30 148 54,00 49,00-58,00
Activated coagulation
time after protamine
administration (sec)
148 138,00 128,00-147,00
Ventilation (h) 146 10,00 7,00-13,00
Troponin T at postoperative
day 1 (μg/L)
147 0,74 0,40-1,50
Total amount of chest tube
output (mL)
148 1000,00 660,00-1505,00
Lowest body temperature
during cardiopulmonary
bypass (degrees of celsius)
148 32,00 29,50-32,00
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is supposed to be pre-warmed prior to blood insertion.
After 300 seconds of incubation, clot detection begins.
The analyzer timing range is from 6 to 999 seconds.
Evaluation of bleeding
Blood loss after CPB was evaluated in two ways. To esti-
mate bleeding extent after protamine administration we
meticulously documented CTO until chest tubes removal.
The volume of CTO was expressed in mL. The cohort
group was divided into two subgroups according to occur-
rence of excessive postoperative bleeding. Patients were
characterized as bleeders if their CTO exceeded 75th per-
centile of distribution. In addition to, transfusion require-
ments (PRBC in mL, FFP in mL, fibrinogen concentrate in
grams and platelet concentrates in units) were docu-
mented as surrogate markers of bleeding extent. InTEM
variables and ACT were correlated to extent of CTO as
expressed in ml and to quantum of transfusion require-
ments for each blood product.
Statistical analysis
The Kolmogorov-Smirnov test was used for evaluating
the normality of distribution of all continuous variables.
Correlation between CTO and InTEM parameters was
evaluated by Spearman's correlation coefficient. Mann–
Whitney U test was used to evaluate whether the me-
dians on a test variables differ significantly between two
groups. Chi-square statistic test was used to compare a
frequency distribution of observed categorical variables
between the two groups. Receiver operating characteris-
tic curve (ROC) was constructed to assess the ability of
TEM parameters to predict excessive postoperative blood
loss [10]. A value of p < 0.05 was considered statistically
significant. For statistical analysis we used MedCalc®
For Windows (MedCalc Software, Broekstraat 52, 9030
Mariakerke, Belgium).
Results
All patients from sample were discharged from hospital.
Study cohort demographic, surgical, and baseline routine
laboratory findings are presented in Tables 1 and 2.
Total amount of CTO value of 1507,50 mL presented
75th percentile of distribution, thus a cut-off value for
bleeder category. No surgical reexploration was performed
in study cohort. Patients in “Bleeder” category had longer
CPB time (median, 116 vs. 95 min, p = 0.023) and signifi-
cantly lower value of the lowest body temperature during
CPB (median, 30 vs. 32 degrees of Celsius, p = 0.012). Pa-
tients with total amount of CTO exceeding 75th percent-
ile were more frequently transfused with fresh frozen
plasma (51.4% vs. 9.9%, p < 0.001), fibrinogen concentrate
(21.6% vs. 2.7%, p = 0.001) and platelet concentrate (13.5%
vs. 0.9%, p = 0.004). Differences in ACT and InTEMparameters of patient groups according to bleeding ten-
dency are presented in Table 3. InTEM parameters, but
not ACTcorrelated to total amount of CTO (mL) (Table 4).
InTEM parameters with the strongest correlation to CTO
were tested for accuracy in predicting excessive postopera-
tive bleeding using ROC analysis. Accuracies of the InTEM
A 10 (AUC 0.636, p = 0.02), InTEM A 20 (AUC 0.632,
p = 0.02) and InTEM A 30 (AUC 0.630, p = 0.02) are
shown in Figure 1.
When analyzing transfusion outcomes, InTEM CT
parameter was shown to be significantly higher (Median
210 sec vs. 192 sec , p = 0.036) in patients transfused with
FFP. The rest of InTEM parameters as well as ACT did
not differ between patients divided with respect to FFP
transfusion. InTEM CT parameter was significantly longer
Table 2 Basic demographic, laboratory and operative
data statistics of study cohort for categorical variables
Count (N) N (%)
Gender (Male) 105 70,9%
Hiperlipidemia 103 69,6%
Hipertension 123 83,1%
Diabetes mellitus 45 30,4%
Smoking habit 30 20,3%
Beta blockers 113 76,4%
Amiodarone 16 10,8%
Antiplatelet therapy 104 70,3%
Lipid lowering drugs 107 72,3%
Procedure type Isolated CABG 84 56,8%
Valve procedure 34 23,0%
Combined procedure 18 12,2%
Other 12 8,1%
Transfused 116 78,4%
Transfused fresh frozen plasma 30 20,3%
Transfused packed red blood cells 119 80,4%
Transfused Fibrinogen concentrate 11 7,4%
Transfused Platelet Concentrate 6 4,1%
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the rest of InTEM parameters and ACT were not signifi-
cantly different. Notably, no differences were observed in
InTEM and ACT parameters when patients were divided
according to platelet concentrate transfusion.Table 3 Differences in activated coagulation time (ACT) and I
thromboelastometry (InTEM) parameters of patient groups ac
C.T.O. Overall (mL)
INTEM CT Non-bleeder 1
Bleeder
INTEM CFT Non-bleeder 1
Bleeder
INTEM ALFA ANGLE (degrees) Non-bleeder 1
Bleeder
INTEM MCF Non-bleeder 1
Bleeder
INTEM A10 Non-bleeder 1
Bleeder
INTEM A20 Non-bleeder 1
Bleeder
INTEM A30 Non-bleeder 1
Bleeder
Activated coagulation time after protamine
administration (sec)
Non-bleeder 1
BleederDiscussion
The best test to detect hemostatic disturbances and
optimize hemostatic properties after CPB remains unclear.
Conventional laboratory tests are unable to decompose
multifactorial coagulopathy pathogenesis as described by
Paparella et al. [11]. Considering the fact that immediate
and precise diagnosis of the underlying cause of hemostatic
disturbances, which result in excessive bleeding, is essen-
tial, we decided to compare ACT with another bedside
suitable test, TEM with InTEM parameter. Our study
showed that InTEM parameters, but not ACT, significantly
correlated to bleeding extent following CPB. There are sev-
eral advantages of InTEM test over ACT. (1) ACT fails to
predict excessive bleeding. Observed correlations between
ACT and CTO were not significant in our study (p = ns)
which is in line with results recently published by Galeone
et al. [12]. The role of the ACT as a monitor of profound
heparin anticoagulation has also been questioned. Notably,
Metz and coworkers found that maintaining a minimum
ACT during CPB was not necessary if a 300 U/kg intra-
venous heparin dose was administered before CPB [13].
Worthwhile, a profound heparin anticoagulation can be
easily confirmed with TEM using InTEM and HepTEM
tests concurrently. (2) While Murray et coworkers [6]
showed that ACT is not very sensitive to the low hep-
arin concentrations that might be present after protam-
ine reversal, Mittermayr et coworkers [14] described
TEM as a valuable tool for heparin-protamine manage-
ment. Using CT parameter, authors showed that TEM
can be used to distinguish the effects of heparin excess
from those of protamine excess [14]. Heparin reboundntrinsically activated modified rotational
cording to bleeding tendency
N Median Interquartile range P (Mann–Whitney U)
11 194,00 171,00-214,00 0.379
37 198,00 182,00-221,00
11 124,00 98,00-165,00 0.033
37 149,00 103,50-207,50
11 69,00 64,00-74,00 0.016
37 65,00 56,50-72,00
11 55,00 50,00-59,00 0.017
37 51,00 46,00-57,00
11 46,00 41,00-50,00 0.013
37 41,00 36,00-48,50
11 53,00 48,00-57,00 0.016
37 49,00 44,00-54,50
11 55,00 50,00-59,00 0.018
37 51,00 46,50-56,50
11 138,00 127,00-145,00 0.179
37 141,00 131,50-149,50
Table 4 Correlations of activated coagulation time and
intrinsically activated modified rotational
thromboelastometry parameters with total volume of
chest tube discharge (mL)
Spearman's correlation Total amount
of chest tube
output (mL)
Study cohort: 148
patients
InTEM CT Correlation coefficient 0,165
P 0,045
InTEM CFT Correlation coefficient 0,164
P 0,047
InTEM alfa Correlation coefficient −0,199
P 0,015
InTEM MCF Correlation coefficient −0,193
P 0,019
InTEM A10 Correlation coefficient −0,205
P 0,013
InTEM A20 Correlation coefficient −0,201
P 0,014
InTEM A30 Correlation coefficient −0,214
P 0,009
Activated coagulation
time after protamine
administration (sec)
Correlation coefficient 0,053
P 0,519
Blood sampling was performed 15 min after protamine administration.
Figure 1 Receiver operating curve analysis for excessive bleeding pre
A 20 test (AUC 0.632, p = 0.02) and by (c) InTEM A 30 test (AUC 0.630
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nomena after cardiac surgery with CPB [12]. Recently,
Galeone et al. [12] showed ACT not to be able to detect
residual heparin activity, whereas thromboelastography
analysis with and without heparinase allowed the diag-
nosis of heparin rebound [12]. However, no association
was observed between heparin concentration, ACT, and
thromboelastography parameters with postoperative bleed-
ing and need for blood and blood components transfusions
[12]. Contrary to, in our study InTEM CT parameter
significantly correlated to the total amount of CTO. Al-
though statistically significant, this correlation is rela-
tively weak (p = 0.045), focusing CT parameter only to
heparin-protamine management in cases of high InTEM
CT values. (3) Hemostatic disturbances after CPB have
multifactorial etiology due to many components of the
hemostatic system involved in. TEM, but not ACT pro-
vides comprehensive insight into hemostatic properties,
therefore allows possibility to detect the most dominant
underlying cause of hemostatic disorder. (4). Spiess et al.
reported thromboelastography guided hemostatic man-
agement to significantly reduce incidence of overall trans-
fusion and mediastinal re-exploration due to excessive
bleeding [15]. We believe that similar results could be
obtained using TEM. However, such a hemostatic man-
agement should be evaluated through a prospective
randomized controlled trial. In present study, observeddiction using (a) InTEM A 10 test (AUC 0.636, p = 0.02) , (b) InTEM
, p = 0.02).
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of CTO. Aside from heparin-protamine neutralization
management, InTEM parameters provide possibility for
targeted procoagulant blood component administration.
Such a transfusion algorithm deems reasonable especially
if InTEM parameters fall below cut-of values which
delineate bleeding tendency according to the ROC curves.
According to our results we propose following hemostatic
management. In patients with high InTEM CT values we
propose concurrent use of InTEM and HepTEM test with
heparin-protamine management as proposed by Mittermayr
et coworkers [14]. HepTEM test can be used to identify
the presence of heparin and its effects on coagulation by
comparison with the InTEM test. If bleeding occurs
after InTEM-HepTEM heparin neutralization manage-
ment and if InTEM parameters fall below cut-of values
defined with ROC curves, targeted procoagulant blood
components administration should be considered. MCF
parameters significantly correlate to amount of CTO.
Thus, ROC derived cut-off values that correspond to
excessive bleeding may be used as triggers for targeted
administration of procoagulant blood components.
In our study, patients in “Bleeder” category had longer
CPB time (median, 116 vs. 95 min, p = 0.023) and signifi-
cantly lower value of the lowest body temperature during
CPB (median, 30 vs. 32 degrees of Celsius, p = 0.012). It is
well known that CPB alters the hemostatic balance and
predisposes cardiac surgery patients to increased risk of
excessive bleeding [16]. Pathophysiology of excessive
bleeding after CPB has been described by Green et al.
[16]. There are several factors related to CPB that con-
tribute to onset of hemostatic disorder such as: foreign
surface contact [17], consumption of clotting factors [18],
platelet activation and dysfunction [19,20] and fibrinolysis
[21]. In addition to, hemostatic impairment during CPB
arises in some extent from systemic hypothermia that in-
duces kinetic slowing of coagulation, kinin and kalikrein
activation, platelet function and fibrinolysis [22]. The fact
that hypothermia tends to increase bleeding in the cardio-
surgical patients has been intuitively recognized by cardiac
surgeons despite scarce evidence available at the begin-
ning. Canine studies have shown that hypothermia
causes thrombocytopenia [23,24] and activates fibrino-
lytic system [24]. Those results were confirmed in nor-
mal volunteers both in vitro and in vivo [25] suggesting
that adequate rewarming strategy may reduce the need
for less safe alternative such as transfusion of procoagu-
lant blood components.
This study has few limitations. First of all, study was
prospective observational, so transfusion management
was performed according to regular clinical practice. In
our study the attending clinicians, both the anesthesiolo-
gists and surgeons were blinded to InTEM results, there-
fore administering procoagulant blood products mainlyon the clinical grounds. The use of procoagulant blood
products certainly affected the amount of bleeding. This
decrease in amount of bleeding would reduce the degree
of correlation between blood loss and both ACT and
InTEM parameters by reducing the sensitivity of each par-
ameter. Administration of procoagulant blood compo-
nents certainly attenuated correlation coefficients between
hemostatic test values and extent of CTO. However, it
would not be ethically acceptable to evaluate the relation-
ship between point-of-care test values and values of CTO
volume amount in setting without use of procoagulant
blood components administered. In our study all patients
were treated in line with the best available hemostatic
management. However, even if administration of pro-
coagulant blood components distorted and attenuated
correlations, the fact is that correlations were equally dis-
torted for each test at the same patient as correlations
were analyzed between CTO extent and values of respect-
ive tests. The same explanation applies for tranexaminic
acid which was regularly used for all patients at two time
points, (1) at the induction of anesthesia, and (2) after pro-
tamine administration. Since all patients received tranexa-
minic acid in the same dose and at the same time, we
assume that all patients were well balanced in respect to
possible effects of tranexaminic acid. In conclusion, al-
though the transfusion of procoagulant blood components
and antifibrinolytic agents certainly reduced the correl-
ation coefficients between point-of-care test results and
amount of CTO, the fact is that all patients had the same
hemostatic management. Further, as previously reported
within “Methods” section, patients requiring surgical reex-
ploration for excessive bleeding were supposed to be ex-
cluded from study if bleeding vessel would be identified
during reexploration. During the study period, no surgical
reexploration for bleeding was performed. It is, however,
obvious that CTO is consisted of both “surgical” and
“hemostatic disorder” bleeding. Without surgical reex-
ploration performed it is impossible to detect whether
some proportion of patients was actually bleeding pre-
dominantly due to surgical cause. It is impossible to
extract surgical bleeding from total amount of CTO. Un-
fortunately, it is not feasible to differentiate chest tubes
bleeding volume in respect to surgical or coagulopathic
origin. At our center, surgical reexploration is performed
in each case with suspicion to surgical cause of bleeding
based on consensus between consultant surgeon and
anesthesiologist. We do not have any specific reexplora-
tion criteria based on dynamics of CTO over time as
well as on amount of CTO. Without measurement of
hourly CTO dynamics and clear criteria that suggest
surgical bleeding it is theoretically possible that some
proportion of patients had surgical bleeding even though
they were not reexplorated. That may explain relatively
high cut-of value for excessive bleeding in our study.
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In conclusion, we suggest that patients with InTEM test
parameters below the cut-off values are at increased risk
of excessive bleeding and use of TEM guided hemostatic
management is required. Excessive bleeding with normal
TEM values implies surgical bleeding and administration
of procoagulant blood components such as fresh frozen
plasma, fibrinogen concentrate and platelet concentrate
should not simply be used empirically. Values above the
cut-off values do not imply the fact that the patients will
not bleed, however they may advise to pay attention to
surgical cause of bleeding. Concomitant use of InTEM
and HepTEM tests enables precise detection of low to
moderate heparin concentration [14]. Therefore, TEM
test also enables physician to detect or prevent protamine
excess resulting from empirical or ACT-based additional
protamine administration. Hemostatic disturbances after
adequate heparin-protamine neutralization management
may be easily detected with additional use of ExTEM and
FibTEM assays. This may be very useful, especially in pa-
tients who developed the coagulopathy due to other CPB
associated factors. In such cases, detection of coagulation
factor depletion, platelets and/or fibrinogen dysfunction
may lead to appropriate, “targeted” hemostatic therapy
and more efficient hemostatic management. Such an
approach may help to improve clinical outcome with
lower incidence of excessive bleeding, lower transfusion
requirements with lower incidence of transfusion re-
lated adverse outcomes.
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